Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cellular Signalling|February 4, 2021
Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancerMumin Alper Erdogan, Ahmed Ashour, Erkan Yuca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2012
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectorsLongjiang Shao, Ibrahim Tekedereli, Jianghua Wang, et al.
Oncotarget|March 28, 2020
Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN lossNicci Owusu-Brackett, Ming Zhao, Argun Akcakanat, et al.
Oncotarget|September 7, 2019
TAK228 enhances antitumor activity of eribulin in triple negative breast cancerNicci Owusu-Brackett, Kurt W Evans, Argun Akcakanat, et al.
Molecular Therapy. Nucleic Acids|September 12, 2013
Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast CancerIbrahim Tekedereli, S Neslihan Alpay, Ugur Akar, et al.
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive CancerMing Zhao, Stephen Scott, Kurt W Evans, et al.
Breast Cancer Research : BCR|March 5, 2021
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer modelsSeyed Pairawan, Ming Zhao, Erkan Yuca, et al.
Scientific Reports|November 19, 2023
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancerTurcin Saridogan, Argun Akcakanat, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2017
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type TumorsKurt W Evans, Erkan Yuca, Argun Akcakanat, et al.
Pageof 2